Beam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250 Million Upfront
By Rob Curran
Biotech company Beam Therapeutics struck a deal with Eli Lilly to sell to the drug giant certain rights in its cardiovascular-disease base-editing licensing deal with Verve Therapeutics for $250 million in cash and stock, plus milestone payments.
Beam, based in Cambridge, Mass., will receive $200 million in cash and a $50 million equity investment, and will be eligible to receive up to $350 million more in milestone payments, based on clinical-development goals.
Beam Therapeutics, was the first biotech company to get rights to base editing technology, a less disruptive variant of the Nobel Prize-winning Crispr gene-editing approach. Verve Therapeutics later licensed Beam's technology to prevent cardiovascular disease.
"We believe that single-course gene-editing treatments could be a compelling new therapeutic option for patients at risk of cardiovascular disease, and we look forward to working with Verve toward that goal," said Ruth Gimeno, group vice president, diabetes, obesity and cardiometabolic research at Lilly, in a statement.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
October 31, 2023 06:44 ET (10:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure